Kanumuri says partners seek greater speed-flexibility
Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s fastest growing Contract Research, Development, and Manufacturing Organizations (CRDMO), says a new CMC Process R&D Centre at its integrated R&D campus in Hyderabad will double capacity.
Scheduled for completion by September 2026, the facility will double the company’s Process R&D capacity, while adding new capabilities in peptide development, oligo intermediates & linkers development, formulation development and early phase clinical supplies.
Speaking on the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said on 27 Oct, “As our partners seek greater speed, flexibility, and scientific depth, we are scaling our capabilities to move programs faster and more efficiently through the development continuum. In an environment where timelines are continually compressing, this new centre enhances our ability to combine scientific excellence with execution agility.”
The new CMC Process R&D Centre represents a strategic investment in scale, sustainability, and specialization. Designed to support both Full-Time Equivalent (FTE) and Dedicated Project Capacity (DPC) engagement models, it will enable flexible collaboration with global innovators—from early development to late-stage CMC programs.
This model further strengthens Sai Life Sciences’ position as a preferred partner for integrated drug development, aligned with the growing demand for end-to-end, partnership-driven solutions that deliver on both quality and timelines.
This investment is part of the company’s planned capital expenditure, reflecting a strong business momentum and expanding engagement with global pharmaceutical and biotech partners. The capex is guided by growing demand for larger clinical-scale programs, a robust late-stage development pipeline, and the need for scalable capacity across CMC development and manufacturing.
Sai Life Sciences is a full-service Contract Research, Development & Manufacturing Organization (CRDMO) working with innovator pharma and biotech companies globally to accelerate the discovery, development, and commercialization of small molecules and emerging modalities. Fiinews.com
